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Abstract
Background: We previously reported that depressive personality (the scores of hypochondriasis, depression and
psychasthenia determined by the Minnesota Multiphasic Personality Inventory (MMPI)) and daily hassles of Graves’
disease (GD) patients treated long trem with antithyroid drug (ATD) were significantly higher in a relapsed group than
in a remitted group, even in the euthyroid state. The present study aims to examine the relationship among depressive
personality, emotional stresses, thyroid function and the prognosis of hyperthyroidism in newly diagnosed GD patients.
Methods: Sixty-four untreated GD patients responded to the MMPI for personality traits, the Natsume’s Stress
Inventory for major life events, and the Hayashi’s Daily Life Stress Inventory for daily life stresses before and during
ATD treatment.
Results: In the untreated thyrotoxic state, depressive personality (T-scores of hypochondriasis, depression or
psychasthenia greater than 60 points in MMPI) were found for 44 patients (69%). For 15 (23%) of these patients,
the scores decreased to the normal range after treatment. However, depressive personality persisted after
treatment in the remaining 29 patients (46%). Normal scores before treatment were found for 20 patients (31%),
and the scores were persistently normal for 15 patients (23%). The remaining 5 patients (8%) had higher depressive
personality after treatment. Such depressive personality was not associated with the severity of hyperthyroidism.
Serum TSH receptor antibody activity at three years after treatment was significantly (p = 0.0351) greater in the
depression group than in the non- depression group. The remission rate at four years after treatment was
significantly (p = 0.0305) lower in the depression group than in the non- depression group (22% vs 52%).
Conclusion: The data indicate that in GD patients treated with ATD, depressive personality during treatment
reflects the effect of emotional stress more than that of thyrotoxicosis and that it aggravates hyperthyroidism.
Psychosomatic therapeutic approaches including antipsychiatric drugs and/or psychotherapy appears to be useful
for improving the prognosis of hyperthyroidism.
Background
There are many reports that emotional stress is related to
the onset of hyperthyroidism due to Graves’disease (GD)
[1-4]. Some reports suggest that emotional stress is also
related to the exacerbation and relapse of hyperthyroid-
ism [5-8]. On the other hand, there are many reports
about the existence of various mental disorders such as
irritability, anxiety, depression and mania in GD patients
[9,10]. Generally speaking, such disorders are thought to
be caused by the thyrotoxic condition and could be
improved after treatment because thyroid hormones have
chemical effects to psychological states including reinfor-
cement of b-adrenergic effects. In fact, in small studies,
only an antithyroid drug (ATD) or b blocker improved
depression and anxiety associated with GD [11,12]. How-
ever, in bigger studies, prevalence of anxiety, depression
and cognitive disturbance were often seen in patients in a
euthyroid state after treatment [13-15].
Previously, we have reported that depressive personal-
ity (the scores of hypochondriasis, depression and psy-
chasthenia determined by the Minnesota Multiphasic
Personality Inventory (MMPI) [16]) and daily hassles of
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were significantly higher in a relapsed group than in a
remitted group even in the euthyroid state [8]. These
data suggest that depressive personality in GD during
treatment is caused by not only thyrotoxicosis but also
other factors including premorbid disease personality
and emotional stresses. Alternatively, our data suggest
that depressive personality during treatment aggravates
the prognosis of ATD treated hyperthyroidism. To clar-
ify the relationship among depressive personality, thyr-
oid function, emotional stresses and the prognosis of
hyperthyroidism, we have done this prospective study to
reanalyze the relationships in new, untreated GD
patients.
Methods
Eighty newly diagnosed GD patients were asked to fill out
questionnaires at two timings; when in a thyrotoxic state
before ATD treatment and in a euthyroid state during
ATD treatment (after 6-12 months: average 7 months).
The questionnaires; contained several measures of psy-
chological factors and were mailed back to the authors.
Of the patients contacted, all 80 signed a consent form,
and 64 (10 males and 54 females, 34.5 ± 13.2 years old)
responded. The MMPI, the Natsume’sS t r e s sI n v e n t o r y
[17] and the Hayashi’s Daily Stress Inventory [18,19]
were given to all participants. Depressive personality was
diagnosed when the T-scores of hypochondriasis, depres-
sion or psychasthenia were greater than 60 points on the
MMPI, according to the results of our former study. The
relationships among depressive personality, thyroid func-
tion, and emotional stresses (life events and daily life
stress) were then evaluated. The relationships between
depressive personality and the prognosis of hyperthyroid-
ism was also evaluated prospectively in 48 patients who
could be followed for 48 months, excluding 16 patients
who dropped out. The initial dose of ATD was thiama-
zole 15~30 mg/day according to the level of thyrotoxico-
sis of each patient, and the dose of ATD was gradually
redused to maintain a euthyroid state. Thiamazole was
changed to propylthiouracil due to a severe drug reaction
by one patient. When, after ATD treatment for at least
12 months, normal serum free T4 and TSH concentra-
tions continued for more than 6 months with thiamazole
2.5 mg/day or propylthiouracil 25 mg/day therapy and
TRAb activity was negative, ATD treatment was stopped.
Patients who maintained normal serum free T4 and TSH
concentrations for more than 12 months after ATD with-
drawal, excluding relapsed patients, were judged as being
inremission.
Tests for Psychological Assessment
Three questionnaires were presented to each subject. In
order to examine ten clinical scales of personality traits,
the Japanese version of MMPI with 383 items developed
by Tanaka et al [20], originally developed by Hathaway
and McKinley was used. The three standard validating
scales included lie, validity, correction and the 10 clini-
cal scales including hypochondriasis, depression, conver-
sion hysteria, psychopathic deviation, masculinity and
feminity, paranoia, psychasthenia, schizophrenia, hypo-
mania and social introversion.
In order to assess major life events, the Natsume’s
Stress Inventory developed by Natsume et al with 67
items including 65 events together with two items,
“stress at present"and “ability to tolerate stress”,w a s
used. The events listed were life events in the following
categories: individual life, family life, occupational life
and social life. Although their frequency of occurrence
was low, their impacts on life and the resultant adapta-
tion were usually considerable. Examples include “death
of spouse”, “pregnancy”, “retirement” or “company fail-
ure”.I nt h i si n v e n t o r y ,4 2e v e n t sw e r es i m i l a rt ot h e
“schedule of recent events” created by Holmes and Rahe
[21], and 23 events were newly added to suit Japanese
culture. The studied subjects answered major life events
in the previous 12 months and rated the impact of each
event as 0 to 100 points for comparison with a score of
50 points for the reference-standard of stress strength of
“marriage”.
In order to assess daily hassles (annoyances) and daily
uplifts (positive experiences), the Hayashi’s Daily Life
Stress Inventory with 71 items developed by Hayashi et
al, was used. This inventory was modified from Lazarus
et al’s [22] original questionnaire scales for “daily hassles”
and “daily uplifts” to suit the Japanese life style. Daily
hassles included, for example, the 8 valid scales including
the following “annoyed about life with others”, “annoyed
by lack of time” or “unfulfilled in personal life”. Daily
uplifts included “satisfaction with work”, “enough time
available”,o r“peaceful in home life”. Subjects answered
daily minor events in the last 12 months and rated the
impact of each event as 1 to 3 points. Two scores were
generated; first, the total number of daily minor events
encountered, and second, the hassles scores and uplifts
scores by intensities, i.e. summing the scales per degree
rated.
Thyroid related tests
Serum free T4 and TSH concentrations were determined
by enzyme immunoassay (Dainabott Co.). Serum free T3
concentrations was determined by radio immunoassay
(Ortho Clinical Diagnosis Co.). Serum TRAb activity was
determined by radioreceptorassay (Cosmic Co.). Thyroid
volume was determined by ultrasonography according to
our reported method [23] [Thyroid volume (ml) = 0.7 ×
(r-width(mm) × r-thickness(mm) × r-length(mm) + l-
width(mm) × l-thickness(mm) × l-length(mm))]. The
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Serum free T4 and TSH concentrations were examined
every 1 to 3 months during ATD treatment and the
amount of ATD was regulated to normalize serum free T4
concentration. Serum TRAb activity and the diameter of
t h et h y r o i dg l a n dw e r ee x a m i n e db e f o r et r e a t m e n t ,a n d ,
6,12, 24, 36, and 48 months during treatment.
Statistical Analysis
Grouped data were expressed by mean ± SD. All data
were compared by Student t-test, Mann-Whitney’st e s t
or chi-square test for independence, expressed by p
value. When there were no significant differences of var-
iance analyzed by Barlett test, the data were also com-
pared by one factor analysis of variance (ANOVA).
Results
1. The changes of depressive personality between before
and during treatment (Figure 1)
In the untreated thyrotoxic state, depressive personality
was found in 44 patients (69%). Of them, 15 (23%) had
scores decreased to normal range after treatment
(groupC). However, in the remaining 29 patients (46%),
the depressive personality persisted after treatment
(groupA). Normal scores in the untreated state were
found for 20 patients (31%), and the scores were continu-
ously normal for 15 patients (23%) (groupD), while the
remaining 5 patients (8%) had higher depressive person-
ality scores after treatment (groupB).
2. The relationships among depressive personality,
thyroid function, and emotional stresses
Among the four groups of patients (groups A~D), there
were no differences in pre and post treatment serum
FT4 concentrations, or in pre treatment serum FT3 con-
centrations, serum TRAb activity, thyroid volume or
131I-uptake (Figure 2). Thirty four patients with depres-
sive personality, even in the euthyroid state (group A
and B) had significantly (p = 0.003) lower daily uplifts
than the remaining 30 patients without depressive per-
sonality (group C and D) (Figure 3).
3. Comparison of the prognosis of hyperthyroidism
between the depression and non- depression groups.
(Figure 4)
Forty-eight patients were followed for four years. There
were no differences in serum FT4 and TSH concentra-
tions before or during treatment between the two
groups. Serum TRAb activity at three years after ATD
treatment was significantly (p = 0.0351) greater in the
23 patients with depressive personality than in the 25
patients without depressive personality (Figure 4). The
rate of remission at four years after treatment was sig-
nificantly (p = 0.0305) lower in the depression group
than in non- depression group (22% vs 52%).
Discussion
The principal finding of our study was that there were
many GD patients who had depressive personality even
Figure 1 Changes of the depressive personality of Graves’ disease patients before and during treatment. GroupA: depressive personality
was present before and persisted after treatment. GroupB: depressive personality scores became higher after treatment. GroupC: depressive
personality was present before treatment and decreased to within the normal range after treatment. GroupD: depressive personality did not
appear either before or after treatment.
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abnormalities during treatment were only sequelae of
thyrotoxicosis, it would be expected that these abnorm-
alities would have a tendency to improve after treatment
and a tendency to continue more often in patients with
greater thyrotoxicosis. However, in our study, depressive
personality before treatment improved in only 15 of 44
patients and it appeared for the first time after treat-
ment in 5 patients. Additionally, whether or not depres-
sive personality exists is not associated with either
thyroid function or severity of hyperthyroidism, includ-
ing TRAb activity, thyroid volume and
131I uptake. On
the other hand, the patient group with depressive per-
sonality had a lower prevalence of daily uplifts than did
the patient group without depressive personality. These
results suggest that such depressive personality as seen
in GD is caused by emotional stresses or premorbid
personality rather than by the chemical effects of the
thyroid hormone, contrary to former consensus.
Secondly, the rate of remission at four years after ATD
treatment was significantly lower in the depression group
than in the non- depression group. These results suggest
that depressive personality, even when euthyroid during
treatment, in GD is related to the aggravation of
hyperthyroidism. Because depressive patients experience
more daily hassles and fewer daily uplifts than non-
depressive patients, emotional stresses may aggravate
hyperthyroidism by the neuro- immuno-endocrine sys-
tem [24] in depressive patients. Although in this study
remission was judged by normal serum free T4 and TSH
concentrations for more than 12 months after ATD with-
drawal, a time interval of 12 months may be too short to
prove stable remission. Further observation should be
made. Controls including healthy population groups or
Figure 2 Comparisons of thyroid functions and severity of hyperthyroidism among four groups. The data from each group are shown as
mean ± SD. GroupA(29): depressive personality was present before and persisted after treatment. GroupB(5): depressive personality scores
became higher after treatment. GroupC(15): depressive personality was present before treatment and decreased to within the normal range after
treatment. GroupD(15): depressive personality did not appear either before or after treatment. There were no significant differences in any
parameters among the four groups by ANOVA.
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group (34) and open bar express the non- depression group (30). The data from each group are shown as mean ± SD. Significant difference: *P
< 0.005 by Mann-Whitney’s test.
Figure 4 Comparison of the prognosis of hyperthyroidism between the depression and non-depression groups. The data from each
group are shown as mean ± SD. The gray zone express the normal ranges. Significant difference: *P < 0.05 by Student t-test. Remission rate:
depressive group 22% (5/23) vs non-depressive group 52% (13/25) (P < 0.05 by chi-square test).
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necessary in future studies to clarify the relationships.
Recently, we have experienced three cases of first
remission after long term ATD treatment together with
antidepressants in GD patients with depression [25].
There are brief reports in which the administration of a
minor tranquilizer together with ATD increased the
remission rate of hyperthyroidism [26,27]. In another
study [28], we found that rational thinking and expres-
sing feelings are associated with early remission in ATD
treated GD patients. Psychotherapy for improving
rational thinking and expression of feelings may also be
useful in improving the prognosis in GD patients with
depression [29].
In conclusion, our findings suggest that in ATD trea-
ted GD patients, depressive personality during treatment
when patients are euthyroid reflects the effect of emo-
tional stresses rather than thyrotoxicosis and that it
aggravates hyperthyroidism. Intervention studies with
psychosomatic therapeutic approaches, including anti-
psychiatric drugs and psychotherapy, should be carried
out with large numbers of patients.
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